Bristol-Myers Squibb Submits Applications in U.S. and Europe to Market Entecavir, an Investigational Antiviral Treatment For Chronic Hepatitis B Infection

Article

PRINCETON, N.J. -- Bristol-Myers Squibb Company today announced the submission of a New Drug Application to the Food and Drug Administration (FDA) for entecavir, an investigational antiviral agent under development for the treatment of chronic hepatitis B.

 

In the European Union, the company also submitted a marketing authorization application for entecavir to the European Medicines Evaluation Agency.

   

Entecavir is an investigational oral antiviral discovered at Bristol-Myers Squibb that is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.

   

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

 

Source: Bristol-Myers Squibb Company

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
Brenna Doran, PhD, MA, who specializes in hospital epidemiology and infection prevention at the University of California, San Francisco, and is a coach and consultant in infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control at Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, PhD, RN, CIC, an associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio.
Jill Holdsworth, MS, CIC, FAPIC, NREMT, CRCST, CHL, an infection preventionist from Atlanta, Georgia.  (Photo credit: Tori Whitacre Martonicz)
"Top 5" in a blue ribbon  (Adobe Stock 235182652 by Evgeny)
© 2025 MJH Life Sciences

All rights reserved.